Literature DB >> 23972508

Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion.

Myriam Marque1, Agathe Roubertie2, Audrey Jaussent3, Maryline Carneiro2, Laurent Meunier1, Bernard Guillot4, Lucile Pinson5, Stéphane Pinson6, Didier Bessis7.   

Abstract

BACKGROUND: Children with multiple café-au-lait macules (CALMs) may be followed for years before a second National Institutes of Health clinical criterion of neurofibromatosis type 1 (NF1) develops to confirm the diagnosis.
OBJECTIVE: We sought to assess the prevalence of nevus anemicus (NA) in NF1 and its association with neuro-ophthalmologic complications.
METHODS: This was a prospective multicenter case-control study of 210 consecutive patients with multiple CALMs. Patients with NF1 were matched for age, sex, and center with control subjects. We documented the number, location, and morphologic appearance of NA; dermatologic features of NF1; magnetic resonance imaging results; and family history.
RESULTS: In all, 77 (51%) patients with NF1 had NA compared with 6 (2%) control subjects. NA was not detected in 26 patients with other genodermatoses associated with CALMs. Patients with NF1 and NA were younger than those without NA (median age: 17 years) (P = .002). NA was mostly localized to the upper anterior aspect of the chest. NA was not significantly linked with other clinical manifestations of NF1, including optic glioma and unidentified bright objects. LIMITATIONS: A potential referral bias associated with tertiary care centers is a limitation.
CONCLUSIONS: NA appears to have a high prevalence and specificity in NF1 and might serve as a marker for NF1 in children with multiple CALMs.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CALM; JXG; Legius syndrome; NA; NF1; NIH; National Institutes of Health; OG; PN; UBO; café-au-lait macule; café-au-lait macules; juvenile xanthogranuloma; neurofibromatosis type 1; nevus anemicus; optic glioma; plexiform neurofibroma; unidentified bright object

Mesh:

Year:  2013        PMID: 23972508     DOI: 10.1016/j.jaad.2013.06.039

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

2.  Molecular Characterization of NF1 and Neurofibromatosis Type 1 Genotype-Phenotype Correlations in a Chinese Population.

Authors:  Jia Zhang; Hanxing Tong; Xi'an Fu; Yong Zhang; Jiangbo Liu; Ruhong Cheng; Jianying Liang; Jie Peng; Zhonghui Sun; Hong Liu; Furen Zhang; Weiqi Lu; Ming Li; Zhirong Yao
Journal:  Sci Rep       Date:  2015-06-09       Impact factor: 4.379

3.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

4.  Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

Authors:  Ellen Denayer; Eric Legius
Journal:  Acta Derm Venereol       Date:  2020-03-25       Impact factor: 3.875

5.  Nevus anemicus and RASopathies.

Authors:  Charlotte Bulteel; Marie-Anne Morren; Petra De Haes; Ellen Denayer; Eric Legius; Hilde Brems
Journal:  JAAD Case Rep       Date:  2018-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.